1. Home
  2. TLSA vs HUMA Comparison

TLSA vs HUMA Comparison

Compare TLSA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.68

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Humacyte Inc.

HUMA

Humacyte Inc.

N/A

Current Price

$0.54

Market Cap

165.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
HUMA
Founded
2013
2004
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
165.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
TLSA
HUMA
Price
$0.68
$0.54
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
★ $7.87
$1.64
AVG Volume (30 Days)
522.3K
★ 4.4M
Earning Date
05-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.37
EPS
★ N/A
N/A
Revenue
N/A
★ $2,038,000.00
Revenue This Year
N/A
$98.07
Revenue Next Year
N/A
$480.72
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.34
52 Week High
$1.90
$1.53

Technical Indicators

Market Signals
Indicator
TLSA
HUMA
Relative Strength Index (RSI) 46.12 54.36
Support Level $0.57 $0.36
Resistance Level $1.21 $0.62
Average True Range (ATR) 0.10 0.06
MACD 0.01 0.01
Stochastic Oscillator 55.24 56.57

Price Performance

Historical Comparison
TLSA
HUMA

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: